Orbimed Advisors LLC bought $5.5M of STTK
director at Shattuck Labs, Inc.. 6,306,127 shares at an average of $0.87, traded Aug 25, 2025, filed Sep 2, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.5M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context74% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +134.7%, 3m +145.5%, 6m +318.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-25-000840, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 25, 2025 | POpen-market purchase Common Stockindirect: See Footnote | +5,255,106 | $0.87 | $4.6M | 5,255,106 | Sep 2, 2025 |
| Aug 25, 2025 | POpen-market purchase Common Stockindirect: See Footnote | +1,051,021 | $0.87 | $912k | 1,051,021 | Sep 2, 2025 |
| Aug 25, 2025 | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +10,111,384 | - | - | 10,111,384 | Sep 2, 2025 |
| Aug 25, 2025 | POpen-market purchase Pre-Funded Warrants (right to buy)derivativeindirect: See Footnote | +2,022,277 | - | - | 2,022,277 | Sep 2, 2025 |
| Aug 25, 2025 | POpen-market purchase Common Warrants (right to buy)derivativeindirect: See Footnote | +15,366,490 | - | - | 15,366,490 | Sep 2, 2025 |
| Aug 25, 2025 | POpen-market purchase Common Warrants (right to buy)derivativeindirect: See Footnote | +3,073,298 | - | - | 3,073,298 | Sep 2, 2025 |
Related signals
Other insiders at Shattuck Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Shattuck Labs, Inc. | Abhinav A. Shukla Chief Technical Officer | $2,874 410 shares | -0% | |
| 20Weak | Shattuck Labs, Inc. | Arundathy N. Pandite Chief Medical Officer | $210k 30,000 shares | -18% | |
| 4Weak | Shattuck Labs, Inc. | Abhinav A. Shukla Chief Technical Officer | $166k 23,465 shares | -21% | |
| 42Moderate | STTKbuy Shattuck Labs, Inc. | Clay B Siegall director | $250k 62,500 shares | +24% | |
| 20Weak | Shattuck Labs, Inc. | Arundathy N. Pandite Chief Medical Officer | $198k 30,000 shares | -15% | |
| 0Weak | Shattuck Labs, Inc. | Abhinav A. Shukla Chief Technical Officer | $14k 2,032 shares | -2% | |
| 64Notable | Shattuck Labs, Inc. | Mona Ashiya director | $5.5M 6,306,127 shares | - | |
| 26Weak | STTKbuy Shattuck Labs, Inc. | Redmile Group, LLC director, owner | $167k 133,371 shares | +2% | |
| 26Weak | STTKsell Shattuck Labs, Inc. | Redmile Group, LLC director, owner | $167k 133,371 shares | -2% | |
| 0Weak | Shattuck Labs, Inc. | Stephen Stout See Remarks | $169k 16,004 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.